Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

PONTE VEDRA, Fla., July 14, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today…